ENDURING MATERIALS: HTRS 2021 Scientific Symposium
Jointly provided by Postgraduate Institute for Medicine (PIM) and the Hemostasis and Thrombosis Research Society (HTRS), the HTRS 2021 Enduring Materials will be available for continuing medical education accreditation 1-year post-conference. This activity is supported by independent educational grant from Takeda, CSL Behring, Novo Nordisk, Inc., Grifols, Sanofi Genzyme, Spark Therapeutics, and Pfizer. If you have questions about the HTRS enduring program for CME/CE credit please email [email protected]
Newly Updated Available Credits per Category: Physicians 14.50 credits | Nurses 14.50 credits | APRN 3.50 credits | Pharmacists 14.50 credits
If you registered to participate in the HTRS 2021 Scientific Symposium virtual conference: You do not need to register again. All HTRS 2021 registrants receive open access to the enduring materials. Please email [email protected] if you need your login credentials.
Access to Enduring Materials for Original HTRS 2021 Registrants/Attendees
Log in with the email address used to register for HTRS 2021 (or the username provided to you by HTRS) and the meeting password you received with your original registration materials. If you forgot your login or need help accessing the portal, email [email protected].
Login to the HTRS 2021 Meeting Site:
Direct Link to Enduring Materials (Login Required):
Access to Enduring Materials for New Registrants
Registration is now open to access enduring materials for HTRS members and non-members who did not previously register, or attend, the live HTRS 2021 Scientific Symposium. For more info including fees, new registrants should visit www.htrs2021.org. To create a new registration for HTRS 2021: CLICK HERE
HTRS members, visit the Members-Only page on this website for your discount code. After you register to access enduring materials, HTRS will provide you with login credentials. Enduring materials are available to new registrants until March 14, 2022.
Click Here to Register:
HTRS Members: Discounted member code for registration
HTRS members received a discounted member registration code via email. If you have not received the member code, email HTRS at [email protected] to request it. For HTRS members only, you may also find the code in the Members Only section of this website.
HTRS 2021 Scientific Symposium Mailing Lists: SCAM ALERT
Be aware that a company called AppendStarpro is fraudulantly representing HTRS and selling fake attendee lists from the virtual conference. HTRS is not represented by this company or their contact Josey Hollis. Their outreach is a scam; do not engage.
HTRS would not work with third-party companies to sell mailing lists or any other attendee info. If you are contacted by a company or individual offering to sell lists on behalf of HTRS, please consult our team first before engaging. Most HTRS sponsorship packages include registrant mailing lists or e-blast campaigns to registrants and/or members depending on the sponsor level.
If you are interested in purchasing attendee lists, please contact HTRS directly. Questions? Email us: [email protected] or [email protected].
HTRS PPE: Wedding Bell Bling!
Congrats to one of our recent HTRS Trainee Workshop participants and his bride, both of whom proudly sported HTRS PPE bling on the big day! Send a snap of you wearing yours to [email protected], and we may feature it on our website or Twitter page @HTRSToday.
Dr. Fauci praises Dr. Lisa Baumann Kreuziger for her work on national COVID-19 panel
Dr. Lisa Baumann Kreuziger, MD, MS, Medical Director at the Versiti Blood Center of Wisconsin, was praised in a personal letter of gratitude from White House advisor and director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci.
A hematology expert, Dr. Baumann Kreuziger is serving on a national COVID-19 panel that recommends the best treatment options for people with the virus. The guidelines have been developed to inform clinicians how to care for patients with COVID-19, she says.
"You responded in an exceptional way and worked tirelessly to develop an outstanding initial set of guidelines in two weeks," wrote Dr. Fauci. "In the first week after their release on April 21, there were more than 1 million page views, highlighting the importance of your work. Thank you again for your contributions to this panel, for your outstanding work in caring for patients and for all the additional ways you are helping to respond to this pandemic during this most extraordinary time."
Says Dr. Baumann Kreuziger, "I was honored and humbled to be part of a group of experts to establish treatment recommendations. The guidelines have provided a review of evidence on which doctors can treat patients and develop research."
Abstracts at ASH 2020
For an updated listing of HTRS members' accepted abstracts at ASH 2020 -- oral and poster presentations, as well as special interest sessions, CLICK HERE
NHLBI News: Blueprint, Strategies and Tools for Future Factor VIII Inhibitor-Related Research
Factor VIII Inhibitor State of the Science Workshop Proceedings were published in the July 2019 edition of Hemophilia - Volume 24, Issue 4.
Abstracts from 2019 Symposium published in Haemophilia
The Abstracts from the HTRS/NASTH 2019 Scientific Symposium were published in Haemophilia, the official journal of HTRS.
Podcast: NHLBI Resources and Grants for Hematologists
How to maximize research training and funding opportunities for non-malignant hematology and blood science investigators is the subject of this free podcast, in which Dr. Donna DiMichele and Dr. Keith Hoots of the National Heart, Lung, and Blood Institute (NHLBI) talk about NHLBI and National Institutes of Health resources and grants available to hematologists.
Join a Registry
The Children’s Hospital-Acquired Thrombosis (CHAT) Study
HTRS and ISTH Announce Strengthened Collaboration
New official journal affiliation with RPTH
HTRS and the International Society on Thrombosis and Haemostasis (ISTH) are excited to announce a new formalized collaboration to further the missions of both organizations. While our two leading medical research societies have worked together for decades, this strengthened partnership launches several concrete initiatives to further advance care for people with hemostatic and thrombotic disorders.
Specifically, an official journal affiliation is newly minted between HTRS and ISTH’s Gold Open Access journal, Research and Practice in Thrombosis and Haemostasis (RPTH), featuring these details:
- RPTH will be listed by HTRS as its leading journal affiliation; however, HTRS will retain its two current journal affiliations with Thrombosis Research and Haemophilia
- RPTH will publish up to four Mentored Review Articles annually, authored by HTRS-member early career investigator/trainees and their mentors; these articles will undergo peer review, and if accepted will be published as “HTRS Mentored Review Articles”
- RPTH will publish up to four articles annually, authored by recipients of HTRS research award programs; these articles will also undergo normal peer review, and if accepted, they will be published as “HTRS Research Award Articles”
As a key feature in this new alignment, RPTH will publish abstracts accepted to the HTRS biennial Scientific Symposium, beginning with the HTRS 2021 Scientific Symposium recently completed this March. Starting in 2023, RPTH will publish Illustrated Abstracts prior to the Scientific Symposium, highlighting the contributions of invited speakers. Additional collaboration throughout the year surrounds joint marketing and communications opportunities.
For more info, CLICK HERE
Foundation for Women & Girls with Blood Disorders - Live Webinar on Thursday, April 29, 2021
Topic: "Vaccine Induced Thrombotic Thrombocytopenia: What We Know & Don’t Know"
Presenter: HTRS Member Gowthami M. Arepally, MD, Professor, Duke University Medical Center
Date and Time: Thursday, April 29, 2021, 12:00 - 1:00 PM ET
This state-of-the-science Webinar will detail and disseminate information related to the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia (VITT) post-vaccination. The Webinar will feature a leading expert in the area of heparin-induced thrombocytopenia (HIT) who will provide an overview of this emerging HIT-like disorder, as well as the most recent information regarding its background, diagnosis, and clinical management. The presentation will be followed by a brief Q & A with the audience.
Announcing the Clive Kearon Guideline Fellowship for the Journal CHEST
Nominations Due: May 14, 2021
The two-year Clive Kearon Guideline Fellowship acquaints early career clinicians with key aspects of guideline development, dissemination, and implementation. The program will honor a key contributor to CHEST guidelines, Clive Kearon, MD, PhD, and build a group of engaged and informed clinicians who understand the complexity of the guideline development process and challenges for maximizing widespread dissemination and implementation.
For more info, CLICK HERE
To apply, CLICK HERE
Rare Bleeding Disorders Elevated on the National Health Agenda
New Commitment from National Hemophilia Program Coordinating Center and Treatment Centers
Hemophilia has been named recently as one of only two rare bleeding disorders in Healthy People 2030 (HP2030), identified as a pressing public health issue alongside conditions such as cancer, diabetes, and heart disease. Released by the U.S. Department of Health and Human Services in August 2020, HP2030 is a focused list of national objectives that aims to track and improve the health and well-being of society over the next decade.
One of these priorities, BDBS-01, will strive to reduce the proportion of people with severe hemophilia who have more than four joint bleeds per year. Inclusion of BDBS-01 is significant for the hemophilia community.
"Inclusion of bleeding disorders as a priority on the national health agenda is an important achievement and has resulted from a coordinated, dedicated advocacy by our community," said HTRS Member Amy Shapiro, MD, CEO and co-medical director at the Indiana Hemophilia & Thrombosis Center, Inc., a member HTC within the Great Lakes Regional Hemophilia Network. "Together with our federal partners and treatment centers across the country, we are committed to achieving this goal."
Data on BDBS-01 is gathered at more than 140 HTCs in the U.S. through the Community Counts: CDC Public Health Surveillance Project for Bleeding Disorders on individuals of all severity of disease. HTC diligence has assisted in elevating these chronic conditions to a level of national public health awareness.
To learn more, click:
Newly published in Blood Advances:
2020 ASH Clinical Practice Guidelines on Treatment of Deep Vein Thrombosis and Pulmonary Embolism
The 2020 ASH Clinical Practice Guidelines on Treatment of Deep Vein Thrombosis and Pulmonary Embolism have been published in Blood Advances.
To access, CLICK HERE
You may also copy and paste the following URL in your browser:
2020 ASH ISTH NHF WFH Clinical Practice Guidelines on von Willebrand Disease
The ASH ISTH NHF WFH Clinical Practice Guidelines on von Willebrand Disease have been published in Blood Advances.
To access, CLICK HERE or download these documents:
HTRS members are also encouraged to review a new proposal for definitions in von Willebrand Disease that was recently published in Blood Advances.
To access this proposal, CLICK HERE.
NHF: Research Project Funding Opportunities
The National Hemophilia Foundation (NHF) offers funding opportunities for bleeding disorders investigators at all career stages who are interested in inherited bleeding disorders research or clinical projects.
Application deadlines are approaching in February, March, April and May 2021. For a full listing of award opportunities, please CLICK HERE.
The Jeanne Marie Lusher Predoctoral Diversity Fellowship seeks research applicants from communities of color and/or those that are nationally underrepresented with the aim of increasing diversity in benign hematology. For more info, CLICK HERE.
Questions, Contact NHF's Research Department at [email protected].
National Institutes of Health Center for Scientific Review
The Center for Scientific Review (CSR) at the National Institutes of Health (NIH) offers two programs that could be valuable for HTRS members:
EARLY CAREER REVIEWER PROGRAM:
Early career scientists who would like review experience can apply to participate in the NIH Early Career Reviewer (ECR) Program. The goals of the ECR Program are to help early career scientists become more competitive as grant applicants through first-hand experience with peer review and to enrich and diversify CSR's pool of trained reviewers.
For more info or to apply to the ECR Program, please CLICK HERE
SCIENTIFIC SOCIETY- REVIEWER RECOMMENDATIONS PORTAL:
HTRS members are invited to recommend scientists to serve as grant reviewers through the NIH Review Recommendation portal. Reviewers should be scientists who are generally willing to serve as reviewers and are seen as experts, with integrity, in their field. They should have an active research program, extramural funding, and not currently be a standing member of an NIH study section or advisory council. The NIH is encouraging HTRS to recommend productive scientists from diverse backgrounds and career stages – e.g. assistant, associate, and full professors.
If you would like HTRS to nominate you or a colleague as an NIH reviewer, please email [email protected] for more info.